A Phase 3 interventional study of Fecal Microbiome Transplantation (FMT) and FMT Placebo in Decompensated Cirrhosis, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase III, multicenter, double-blind, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated cirrhosis.
Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients admitted to the hospital for acute decompensation of the disease. These patients could be included after discharged as long as they do not present any of the following events:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A first dose of 24 capsules of FMT at baseline and a second dose of 24 capsules of FMT at 3 months. Each dose (24 capsules) contains approximately 50g of stool.
Drug: Fecal Microbiome Transplantation (FMT)
A first dose of 24 capsules of FMT placebo at baseline and a second dose of 24 capsules of FMT placebo at 3 months. Each dose (24 capsules) contains in total 6 g of microcrystalline cellulose or equivalent.
Other: FMT Placebo
Two doses: First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months.
Two doses: First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months.
Efficacy of treatment in halting the progression of decompensated cirrhosis.
Assessed by time to first decompensation event (acute kidney injury (AKI), ascites, bacterial infection, gastrointestinal bleeding, HE).
Time frame: Screening to month 12.
Time to transplant-free survival
Assessed by transplant-free survival
Time frame: At month 1, month 3, month 6 and month 12
Mortality rates
Assessed by mortality rates
Time frame: At month 1, month 3, month 6 and month 12
Rate of patients developing/ worsening individual complications of cirrhosis.
Assessed by ascites, acute kidney injury, bacterial infections, gastrointestinal bleeding and hepatic encephalopathy.
Time frame: At baseline, month 1, month 3, month 6 and month 12.
Frequency of hospital admissions due to complications of cirrhosis.
Assessed by hospital admissions due to complications of cirrhosis.
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Development of acute-on-chronic liver failure (ACLF)
Assessed by time to first episode of ACLF
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Development of acute-on-chronic liver failure (ACLF)
Assessed by total number of patients developing ACLF
Time frame: At month 3, month 6 and month 12.
Development of acute-on-chronic liver failure (ACLF)
Assessed by severity of ACLF episodes based on ACLF grade (from grade 1 to grade 3) and CLIF-C-ACLF score
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Development of acute-on-chronic liver failure (ACLF)
Assessed by number and type of organ failures
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Changes from baseline in systemic inflammatory response.
Evaluated by measurement in a large array of plasma cytokine levels including, but not limited to TNFα, IL-6, IL8, IL-10, IL-1β, IFN-ɣ, G-CSF, VCAM, VEGF, as well as an oxidized form of albumin, human nonmercaptalbumin-2 (HNA2).
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
PBMCs phenotype and function.
Analysed by flow cytometry, functional analysis, and RNAseq single cell analysis.
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Changes from baseline in different plasma and urine prognostic biomarkers.
Measurated by different plasma and urine prognostic biomarkers including, but not only, copeptin, NGAL, PD-L1, L-FABP.
Time frame: At baseline, 1 month, 3 months, 6 months, and 12 months.
Changes from baseline in systemic hemodynamics and vasoactive hormones.
Measurated by systemic hemodynamics and vasoactive hormones: plasma renin concentration and plasma copeptin.
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Changes from baseline in blood levels of bacterial DNA or bacterial products.
Measurated by blood levels of bacterial DNA or bacterial products.
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Changes from baseline in liver function.
Evaluated by MELD (Model for End-stage Liver Disease) score.
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Changes from baseline in liver function.
Evaluated by CLIF-AD score.
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Changes from baseline in liver function.
Evaluated by Child Pugh Score.(from 1 point to 15 points)
Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.
Analyze microbiome composition from saliva and stool.
Measurated by analysis of microbial genes.
Time frame: At baseline, and months 1, 3 and 6.
Changes in hepatic venous pressure gradient (HVPG) from baseline.
Measurated by the hepatic venous pressure gradient.
Time frame: At baseline and month 6.
Assess Quality of life, functional assessment and in Minimal Hepatic Encephalopathy.
Evaluated with data obtained from CLDQ (Chronic Liver Disease Questionnaire) questionnaire.
Time frame: At baseline, 3 months, 6 months and 12 months.
Assess Quality of life, functional assessment and in Minimal Hepatic Encephalopathy.
Evaluated with data obtained from Liver Frailty Index.
Time frame: At baseline, 3 months, 6 months and 12 months.
Assess Quality of life, functional assessment and in Minimal Hepatic Encephalopathy.
Evaluated with data obtained from PHES (Psychometric Hepatic Encephalopathy Score) questionnaire.
Time frame: At baseline, 3 months, 6 months and 12 months.
Changes from baseline in AUDIT test.
Evaluated from AUDIT test
Time frame: AUDIT test at baseline, 3 months, 6 months and 12 months
Changes from baseline in alcohol consumption.
Evaluated from PETh measurament.
Time frame: PETh measurament test at baseline, 1 month, 3 months, 6 months and 12 months.
Assess the effect of FMT in ECG (Electrocardiogram).
Evaluated by changes in ACE score.
Time frame: At screening, baseline and months 3,6 and 12.
Proportion of patients with treatment-related adverse events.
Evaluated by treatment-related adverse events.
Time frame: Screening to month 12.
Proportion of patients with severe treatment-related adverse events.
Evaluated by treatment-related adverse events.
Time frame: Screening to month 12.
Started Jul 2025 (actual). Primary completion is estimated for Jan 2029, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorcio Centro de Investigación Biomédica en Red (CIBER)